Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 7/20 | 0.43 |
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614209 | 1.00 | PPARA (0.53) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| SCHEMBL1430675 | 1.00 | PPARA (0.53) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| Serine SCHEMBL8588277 | 0.90 | PPARA (0.46) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| Serine SCHEMBL8588281 | 0.90 | PPARA (0.46) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| Benzoic Acid SCHEMBL9540832 | 0.88 | PPARA (0.61) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| SCHEMBL1604541 | 0.87 | SMN1; SMN2 (0.50) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| SCHEMBL615910 | 0.87 | SMN1; SMN2 (0.50) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| SCHEMBL615909 | 0.87 | SMN1; SMN2 (0.50) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| SCHEMBL2241213 | 0.86 | SMN1; SMN2 (0.46) | PPARAPPARGSMN1; SMN2CTSSCTSK | |
| SCHEMBL25755437 | 0.86 | SMN1; SMN2 (0.46) | PPARAPPARGSMN1; SMN2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540162-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-12365674-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-20240092833-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-21 | — | — | US | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2008070733-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070733-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1165613-B1 | MELANOCORTIN RECEPTOR LIGANDS | PROCTER & GAMBLE (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2005030796-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
| WO-1993005011-A1 | NOVEL IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | PPARA 4860/4885PPARG 4858/4885SMN1; SMN2 3689/4885 |
| US-12365674-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC3 | PPARA 3493/4885PPARG 3815/4885SMN1; SMN2 4407/4885 |
| US-12540162-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | PTMS, AHCY, BHMT2 | PPARA 3362/4885PPARG 3024/4885SMN1; SMN2 2229/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | PPARA 1346/4885PPARG 269/4885SMN1; SMN2 49/4885 |
| US-20240092833-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | BHMT2, BHMT, PTMS | PPARA 3694/4885PPARG 4068/4885SMN1; SMN2 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.